Drug Evaluation Committee Conduct and Management of Clinical Trials and Clinical Studies under the Spread of New-type Coronavirus Infections (COVID-19)
Clinical Evaluation Subcommittee
We understand that each company is taking measures in relation to the outbreak of new coronavirus infection in 2020.
Pharmaceutical companies must also take measures to prevent the spread of infection, while conducting clinical trials and clinical studies in an appropriate manner.
The Clinical Evaluation Committee, in collaboration with the Japan SMO Association and the Japan CRO Association, has issued a joint statement entitled "Implementation and Management of Clinical Trials and Clinical Studies under the Spread of New-type Coronavirus Infections (COVID-19)," which we would like to share widely with all concerned parties. We would like to ask all concerned parties to share it widely.
(Clinical Evaluation Subcommittee)
-
As of December 2023
Drug Evaluation Committee Deliverables Return to list of all communications